Pfizer seeks FDA approval for "smart bomb" cancer drug

08/11/2005 | Boston Globe (tiered subscription model), The

Pfizer said it would seek to sell Sutent, the first of a new class of "smart bomb" drugs intended to starve tumors of blood and nutrients, for use against kidney and stomach cancers. Pfizer obtained Sutent in its 2003 acquisition of Pharmacia and hopes it and other cancer drugs will raise the company's profile in oncology treatments.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL